GenAI scaling 3x faster than past tech waves - research (AIQ:NASDAQ)
GenAI revenue is tripling past prior IT waves, set to top $100B by year three.
YayaNews contributes financial news and market context through the YayaNews editorial workflow.
GenAI revenue is tripling past prior IT waves, set to top $100B by year three.
GenAI scaling 3x faster than past tech waves - research (AIQ:NASDAQ) | Seeking Alpha
Copy Link
Save
Play
(
<1min
)
Comments
Vertigo3d/iStock via Getty Images
The generative artificial intelligence (
AIQ
) (
AIEQ
) industry is scaling its revenue at an unprecedented rateâgrowing three times faster than any previous major IT wave, according to new research from Exponential View.
The estimate is based on realized revenue trajectories adjusted
To ensure this doesnât happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.
Search field
Entering text into the input field will update the search result below
Entering text into the input field will update the search result below
Recommended For You
More
Trending News
See More
»
Original YayaNews editorial coverage, published for informational purposes.
This article is sourced from Seeking Alpha. It is for informational purposes only and does not constitute investment advice.
Topics & Symbols
Continue Reading
Related Reading
Rapid7's 2026 Exit Signal: Deep Dive into 20% Margin Target and 12% Workforce Restructuring
Rapid7 announces 2026 exit plan with ~20% non-GAAP operating margin target and 12% workforce restructuring. This analysis explores strategic intent, financial feasibility, and industry context for investors.
P3 Health Partners forecasts $80M-$110M in 2026 adjusted EBITDA following Q2 settlements (NASDAQ:PIII)
P3 Health Partners (PIII) Q2 2026 earnings call recap: EBITDA beat, raised 2026 outlook, settlement impacts, seasonality risks & strategy.
Anaergia reports Q2 results (TSX:ANRG:CA)
Anaergia press release (ANRG:CA): Q2 Revenue of C$63.9M (+97.8% Y/Y). Adjusted EBITDA improved to positive C$1.9 million, compared with an Adjusted EBITDA loss
QuidelOrtho partially recovers from earnings slide, rising 12% (QDEL:NASDAQ)
QuidelOrtho (QDEL) stock rebounds 12% after Q2 earnings beat but sharp 2026 guidance cut.
